Blood Glucose Testing and Diabetes Management

Table of Contents

1. Overview

• 1.1 Statement of Report
• 1.2 About this Report
• 1.3 Scope of the Report
• 1.4 Methodology
• 1.5 Executive Summary

2. Diabetes

• 2.1 Demographics of Diabetes
  • 2.1.1 Worldwide Diabetes Incidence
  • 2.1.2 U.S. Diabetes
• 2.2 Economics of Diabetes
• 2.3 Understanding the Metabolic Conditions Underlying and Associated with Diabetes
  • 2.3.1 Pre-Diabetes Syndrome
  • 2.3.2 Metabolic Syndrome
  • 2.3.3 Diabetes and Inflammation
  • 2.3.4 Progression of Diabetes
  • 2.3.5 Complications and Co-Morbidities in Type 2 Diabetes
  • 2.3.6 Hypoglycemia and Treatment
  • 2.3.7 Risk Factors and Diabetes
  • 2.3.8 Cardiovascular Disease Facts
• 2.4 Glucose Control in Diabetic Patients
• 2.5 Tight Glucose Control in Treating Diabetes
• 2.6 Glucose Monitoring Devices
  • 2.6.1 Key Issues Identified for Glucose Monitoring
  • 2.6.2 Device Description
  • 2.6.3 Precision
  • 2.6.4 Limitations of Existing Glucose Monitoring Products

3. Glucose Measurements

• 3.1 Glucose Monitoring Markets
  • 3.1.1 Overview of Market Segments
    • 3.1.1.1 Over-the-Counter (OTC) Self-Testing Glucose Market
    • 3.1.1.2 Point- of- Care Glucose Testing Market
    • 3.1.1.3 Physician Office Laboratories (POL) Glucose Testing Market
    • 3.1.1.4 Clinical Laboratory Glucose Testing Market
  • 3.1.2 Market Analysis: Size, Growth, Share and Competitors
    • 3.1.2.1 Worldwide Market
    • 3.1.2.2 U.S. Market
    • 3.1.2.3 European Market
    • 3.1.2.4 Asian Market
      • 3.1.2.4.1 Japanese Market
      • 3.1.2.4.2 China Market
      • 3.1.2.4.3 India Market
    • 3.1.2.5 ROW Markets
• 3.2 Glucose Analytical Test Methods
  • 3.2.1 Glucose Oxidase
  • 3.2.2 Glucose Hexakinase
  • 3.2.3 Glucose Dehydrogenase Pyrroloquinolinequinone (GDH-PQQ)
  • 3.2.4 Amperometric Biosensors
  • 3.2.5 Interfering Substances
  • 3.2.6 Monitoring HbA1c Levels
  • 3.2.7 Quality Control Criteria
• 3.3 Reagents and Equipment
  • 3.3.1 Lancets
  • 3.3.2 Blood Glucose Test Kit
  • 3.3.3 Blood Glucose Monitor and Insulin Doser
  • 3.3.4 Diabetes Tracking System
  • 3.3.5 Blood Glucose Sensors
  • 3.3.6 Blood Glucose Reagent Test Strips
  • 3.3.7 Control Solutions and Calibrators
  • 3.3.8 Sharps Devices
  • 3.3.9 Needle Destruction Devices
  • 3.3.10 Urine Strips
  • 3.3.11 Blood Ketone Testing
  • 3.3.12 Voice Operated Glucose Meters
• 3.4 Glucose Meters
  • 3.4.1 LifeScan (a Johnson & Johnson Company)
  • 3.4.2 Roche Accu-Chek
  • 3.4.3 Bayer
  • 3.4.4 Medisense (Abbott)
  • 3.4.5 Acon Laboratories
  • 3.4.6 HemoCue
  • 3.4.7 Agamatrix, Inc.
  • 3.4.8 AiMedics, Pty Ltd.
  • 3.4.9 Apex Biotechnology Corp.
  • 3.4.10 77 Elektronika Kft.
  • 3.4.11 Arkray, Inc.
  • 3.4.12 Becton Dickinson & Co.
  • 3.4.13 Accurex (India)
  • 3.4.14 Biosens
  • 3.4.15 Axis-Shield
  • 3.4.16 Home Diagnostics, Inc.
  • 3.4.17 Medisys/Hypoguard
  • 3.4.18 Metrika
  • 3.4.19 Biopeak, Corp.
  • 3.4.20 BioTex, Inc.
  • 3.4.21 Calisto Medical, Inc.
  • 3.4.22 Allmedicus
  • 3.4.23 Diabetech, LP
  • 3.4.24 Diagnostic Devices
  • 3.4.26 DIRAmed LLC
  • 3.4.27 Entelos
  • 3.4.28 Fifty 50 Pharmacy
  • 3.4.29 Fluent Biomedical Corp.
  • 3.4.30 Fovi Optics, Inc.
  • 3.4.31 GenExel-Sein, Inc.
  • 3.4.32 GlucoLight Corp.
  • 3.4.33 Glucon Medical Ltd.
  • 3.4.34 GluMetrics LLC
  • 3.4.35 Glucoplus, Inc.
  • 3.4.36 GlySens, Inc.
  • 3.4.37 HMD Bio Medical
  • 3.4.38 Hypoguard
  • 3.4.39 Infratec, Inc.
  • 3.4.40 InLight Solutions, Inc.
  • 3.4.41 Insulet Corp.
  • 3.4.42 Integrity Applications
  • 3.4.43 Kumetrix, Inc.
  • 3.4.44 Lein Applied Diagnostics Ltd.
  • 3.4.45 Cholestech
  • 3.4.46 LighTouch Medical, Inc.
  • 3.4.47 LG Electronics
  • 3.4.48 Luminous Medical, Inc.
  • 3.4.49 Menarini Diagnostics
  • 3.4.50 NIR Diagnostics, Inc.
  • 3.4.51 Oculir, Inc.
  • 3.4.52 OrSense Ltd.
  • 3.4.53 Pelikan Technologies, Inc.
  • 3.4.54 Polymer Technology Systems
  • 3.4.55 PreciSense A/S
  • 3.4.56 QuestStar Medical, Inc.
  • 3.4.57 Sensys Medical
  • 3.4.58 Smiths Medical MD, Inc.
  • 3.4.59 TaiDoc Technology Corp.
  • 3.4.60 U.S. Diagnostics
  • 3.4.61 VeraLight, Inc.
  • 3.4.62 Zyvex Corp
  • 3.4.63 Advanced Biosensors
  • 3.4.64 Health Hero Network, Inc.
  • 3.4.65 IN4 Technology Corporation
  • 3.4.66 Nipro
  • 3.4.67 Teco Diagnostics, Inc.
  • 3.4.68 Uchain Industrial Co., Ltd.
  • 3.4.69 GlucoStat System
  • 3.4.70 Sanyo Junyaku
  • 3.4.71 Diagnosys Medical
• 3.5 Diagnosing Diabetes Using In Vitro Laboratory Tests
  • 3.5.1 New Diagnostic Guidelines
  • 3.5.2 Fasting Plasma Glucose (FPG) Test
  • 3.5.3 Glucose Tolerance Test
  • 3.5.4 Test for Glycosylated Hemoglobin
  • 3.5.5 Fructosamine
  • 3.5.6 Combined Self-Testing Glucose Monitor with Insulin Delivery
  • 3.6 Continuous and Non-invasive Glucose Patient Monitoring
  • 3.6.1 Medtronic MiniMed Continuous Glucose Monitoring System
  • 3.6.2 Cygnus GlucoWatch Biographer
  • 3.6.3 Abbott FreeStyle Continuous Glucose Monitor System
  • 3.6.4 DexCom, Inc. STS Continuous Glucose Monitoring System
  • 3.6.5 Sontra Medical, Inc.
  • 3.6.6 SpectRx
  • 3.6.7 Pendragon Medical
  • 3.6.8 Sensors for Medicine and Science, Inc. (SMSI)
  • 3.6.9 Other Players
  • 3.6.10 Strategies for Developing Non-invasive Continuous Glucose Monitoring
• 3.7 Glycosylated Hemoglobin Glucose Monitoring
  • 3.8.1 Ultra-Large Throughput Chemistry Analyzers Large-Throughput Analyzers
  • 3.8.2 Large-Throughput Analyzers
  • 3.8.3 Mid-Size Clinical Chemistry Analyzers
  • 3.8.4 Chemistry Analyzers for the Small Volume Market

4. Business Trends in Glucose Testing

• 4.1 Expanding Opportunities in Blood Glucose Monitoring Market
• 4.2 Home Diabetes Test Kits an Evolving Market
• 4.3 Competitive Strategies
• 4.4 Analyses of the Current Market Conditions, Competition and Product Mix
• 4.5 The New Paradigm
• 4.6 Mergers of Diagnostic Companies
• 4.7 Healthcare Cost Controls
• 4.8 Competition for Services
• 4.9 Drivers of Clinical Glucose Testing
• 4.10 Confluence of New Technology
• 4.11 Trends in Reimbursement Practices
• 4.12 Managed Care
• 4.13 Changes in Patient Management
• 4.14 Satellite Facilities
• 4.15 Point-of-Care Testing
• 4.16 Regionalization of Laboratory Care
• 4.17 Drivers of the Point of Care Testing Sector
• 4.18 Diagnostic Testing Growth Trends
• 4.19 PIPE Financing
• 4.20 Brand Loyalty
• 4.21 Insurance Coverage a Key Factor
• 4.22 Medicare Coverage
• 4.23 Products at Competitive Price Points
• 4.24 Drugstores Critical to the Diabetic Care Category
• 4.25 Drugstore Chains Increasingly Running Diabetes Care Programs
• 4.26 Co-branding Strategies

5. Important Technology Trends

• 5.1 Biosensor Technology
• 5.2 Data Management
  • 5.2.1 Information Management Advances
  • 5.2.2 Patient Care Information System Strategy
  • 5.2.3 Connectivity Platforms
    • 5.2.3.1 DataLink Data Management System
    • 5.2.3.2 RALS-Plus
    • 5.2.3.3 LabPortal.com
    • 5.2.3.4 LifeScan Electronic Data Interfaces
    • 5.2.3.5 Computer Software for Home Glucose Meters
    • 5.2.3.6 Health Buddy Systems Monitoring Technologies
    • 5.2.3.7 Medtronics MiniMed Paradigm Glucose Meter
  • 5.2.4 POL Laboratory Data Management
    • 5.2.4.1 Electronic Medical Record Systems and Physician Office Laboratory Data Linking Software
    • 5.2.4.2 Physician Office Laboratory Data Linking Software and Interface to the Laboratory Information System
  • 5.2.5 Technical Problems of Connectivity
  • 5.2.6 Web-based Data Interface
  • 5.2.7 HIT Competition
  • 5.2.8 FDA Required Software Verification
• 5.3 Advantages of Connectivity
• 5.4 Home Care Analysis
• 5.5 Technology Platform Innovations in Glucose Testing
• 5.6 Move Away from Central Laboratory
• 5.7 Trends in Detection and Diagnosis
  • 5.7.1 Minimally-Invasive Devices
  • 5.7.2 Non-invasive Devices Future Developments and Market Strategy
  • 5.7.3 Continuous Test Systems and the Future of Integrated Glucose/Insulin Delivery

6. Competitive Analysis of the Glucose Testing Markets

• 6.1 The Market Players
• 6.2 Device Categories
• 6.3 Range of Products
  • 6.3.1 Cost of Testing
  • 6.3.2 Sample Size Required
  • 6.3.3 Sampling Other Areas
  • 6.3.4 Time Until Patient Obtains Results
  • 6.3.5 Enclosed Test Strips
  • 6.3.6 Test Strip Calibration
  • 6.3.7 Built-in Lancing Device
• 6.4 Data Handling
• 6.5 New Developments
• 6.6 Marketing New Features
• 6.7 Test Strip Sales
• 6.8 Reimbursement
• 6.9 Strip Manufacturers' Responses
• 6.10 Retailers' Responses
• 6.11 Market Demand and Composition
• 6.12 Product Mix
  • 6.12.1 LifeScan
  • 6.12.2 Roche Diagnostics
  • 6.12.3 Bayer Diagnostics
  • 6.12.4 Becton Dickinson
  • 6.12.5 Abbott (MediSense)
  • 6.12.6 Other Players
    • 6.12.6.1 HemoCue AB
    • 6.12.6.2 Home Diagnostics, Inc.
    • 6.12.6.3 Medisys Group PLC
    • 6.12.6.4 Polymer Technology Systems, Inc.
    • 6.12.6.5 QuestStar Medical, Inc.
• 6.13 Devices that Measure Glycohemoglobin
• 6.14 Adjacent Markets
• 6.15 Market Drivers and Restraints
• 6.16 Market and Product Trends
• 6.17 Increased Market Penetration
• 6.18 Costs of Doing Business in Europe
• 6.19 Drivers of European Diagnostics Testing
• 6.20 European Reimbursement Practices
• 6.21 Cost Containment in Europe
• 6.22 Market Overview of Glucose Monitoring
  • 6.22.1 U.S. Market Segment
  • 6.22.2 European Market
  • 6.22.3 Japanese Market
• 6.23 Competitive Strategies
• 6.24 Price Competition
• 6.25 Analyses of the Current Market Conditions, Competition and Product Mix
  • 6.25.1 First-Generation Monitors
  • 6.25.2 Second-Generation Monitors
  • 6.25.3 Third-Generation SMBG Technologies
• 6.26 Product Overview
  • 6.26.1 LifeScan
• 6.27 Design of Glucose Testing Devices
• 6.28 Insulin Delivery Devices
• 6.29 Key Glucose Testing Sector Developments
• 6.30 Important M&A Activity
  • 6.30.1 Cygnus, Inc. Divests its Glucose-Monitoring Assets to Animas Corporation
  • 6.30.2 Bayer Diagnostics Business Splits into Two Units
  • 6.30.3 Abbott Laboratories Acquires TheraSense, Inc.
  • 6.30.4 Roche Acquires Infusion Systems Division of Disetronic
  • 6.30.5 J&J Acquires Animas Corporation
  • 6.30.6 Medical Devices Pelikan Technologies, Inc.
  • 6.30.7 Medical Services Amerifit Nutrition, Inc.
  • 6.30.8 Owens & Minor, Inc.
  • 6.30.9 Medisys Sells Business to Arkray
  • 6.30.10 Cholestech Signs Agreement with Provalis
  • 6.30.11 Bayer Acquires Metrika
  • 6.30.12 Other Deals
• 6.31 Product Launches

7. Government Regulation of Medical Devices

• 7.1 U.S. Regulations
  • 7.1.1 Importing Medical Devices into the U.S.
  • 7.1.2 Exporting Medical Devices from the U.S.
• 7.2 U.K. Regulations
• 7.3 E.U. Regulations
• 7.4 French Regulations
• 7.5 Japanese Regulations
• 7.6 Korean Regulations
• 7.7 FDA Regulations and Recalls
• 7.8 Legal Liability for Glucose Meters
• 7.9 ISO 9000 Quality System
• 7.10 Recent Regulatory Approvals
• 7.11 FDA Labeling Requirements

8 Corporate Profiles

• 8.1 Abbott Diagnostics
• 8.2 Abbott Laboratories
• 8.3 Acon Laboratories
• 8.4 AgaMatrix
• 8.5 AiMedics Pty Ltd.
• 8.6 Animas Corp.
• 8.7 Apex Biotechnology Corporation
• 8.8 Bayer Corporation
• 8.9 Biopeak Corporation
• 8.10 BioTex
• 8.11 Dexcom, Inc.
• 8.12 Diabetech, LP
• 8.13 77 Elektronika Kft.
• 8.14 Flexsite Diagnostics
• 8.15 GenExel-Sein, Inc.
• 8.16 GlucoLight
• 8.17 Glucon
• 8.18 GluMetrics, Inc.
• 8.19 GlySens, Inc.
• 8.20 Hemocue
• 8.21 Hypoguard
• 8.22 Infratec, Inc.
• 8.23 IN4 Technology
• 8.24 InLight Solutions
• 8.25 ITC (International Technidyne Corporation)
• 8.26 LifeScan Corporation
• 8.27 MediSense
• 8.28 Metrika
• 8.29 NIR Diagnostics
• 8.30 Nipro Medical Corporation
• 8.31 OrSense Ltd.
• 8.32 Pelikan Technologies
• 8.33 Polymer Technology Systems
• 8.34 PreciSense
• 8.35 QuestStar Medical
• 8.36 Roche Diagnostics
• 8.37 Sankyo Junyaku
• 8.38 Sanwa Kagaku Kenkyusho Co., Ltd.
• 8.39 Sensys Medical
• 8.40 SurgiLance
• 8.41 Smiths Medical MD, Inc.
• 8.42 SpectRx
• 8.43 Taidoc Technology
• 8.44 Teco Diagnostics
• 8.45 U.S. Diagnostics
• 8.46 VeraLight

• Appendix 1: List of Competitors for Glucose Test Meters and Equipment
• Appendix 2: FDA Proprietary Devices for Measuring Blood Glucose
• Appendix 3: Overview of FDA Device Regulations
• Appendix 4: Retail Prices of Glucose Meters

INDEX OF FIGURES

• Figure 2.1: Demographic Changes in Diabetes Populations in 2010, 2025 and 2050
• Figure 2.2: How Diabetes Dollars Are Spent in the U.S.
• Figure 2.3: Overlap between Individuals Diagnosed as Diabetic According to Fasting Plasma Glucose Concentration (ADA Criteria) or the Two-Hour Glucose Value (WHO Criteria)
• Figure 2.4: Single Day Continuous Blood Glucose Data
• Figure 3.1: Share of the U.S. Self-Testing Diagnostic Market, 2006
• Figure 3.2: U.S. Mass-Market Sales of Glucose Testing Kits, 2000-2012
• Figure 7.1: World Medical Device Markets
• Figure 7.2: Medical Device Market Share by U.S. Owned Companies

INDEX OF TABLES

• Table 2.1: Normal Glucose Values-Fasting State
• Table 2.2: Population with Diabetes in the World and in Selected Nations, 2000 and 2030
• Table 2.3: U.S. Population of Diabetics by Ethnic Group
• Table 2.4: Percentage of U.S. Adults with Diabetes Using Diabetes Medication by Age Group, 2002-2007
• Table 2.5: Healthcare Utilization by Diabetic Patients
• Table 2.6: Age-Adjusted Percentage of Adults with Diabetes Using Diabetes Medication by Type of Medication U.S., 2002-2007
• Table 2.7: Crude and Age-Adjusted Percentage of Adults with Diabetes Using Diabetes Medication, U.S., 2002-2007
• Table 2.8: Percentages of Adults with Diabetes Using Diabetes Medication by Age, U.S., 2002-2007
• Table 2.9: Annual Estimated Cost of U.S. Diabetes Care
• Table 2.10: Leading Ten Diagnoses by Total U.S. Patient Visits, 2007
• Table 2.11: U.S. Incidence of Diabetes by Age, 2007
• Table 2.12: Prevalence, Cost and Medicines for Major Diseases in the U.S., 2007
• Table 2.13: Top Ten Causes of Death in the U.S., 2007
• Table 2.14: Per-Event Costs of Diabetes Complications
• Table 2.15: Percentage of Persons with Type 1 Diabetes Experiencing Various Complications
• Table 2.16: Incidence and Relative Risk: Patients with Diabetes versus Those without Diabetes
• Table 2.17: Novel Risk Factors and Possible Mechanisms of the Excess Risk of Coronary Heart Disease in Type 2 Diabetes Mellitus
• Table 2.19: Worldwide Market for Cardiac Care Therapeutics, 1999-2010
• Table 2.20: Major Causes of End-Stage Renal Disease
• Table 2.21: Key Features Considered for Glucose Meter Devices
• Table 3.1: Laboratory Assessment of Diabetic Vascular Disease
• Table 3.2: Key Market Drivers for Glucose Testing
• Table 3.3: Key Customer Segments of Glucose Testing
• Table 3.4: Demographic Characteristics Home Testing Kit Buyers
• Table 3.5: Top Brand Preferences for Home Glucose Testing Kits
• Table 3.6: Instances When Patients Prefer Professional' s Glucose Testing
• Table 3.7: Advantages of a Home Testing Kit
• Table 3.8: Disadvantages of Using a Home Testing Kit
• Table 3.9: Popular Shopping Destinations for Buying or Seeking Information on Home Testing Kits
• Table 3.10: Total Dedicated U.S. Professional Glucose Testing Market, 2000-2012
• Table 3.11: Point of Care Glucose Testing U.S. (Hospitals), 2000-2012
• Table 3.12: U.S. POL Glucose Testing, 2000-2012
• Table 3.13: U.S. Central Lab Glucose Testing (Hospitals and Reference Labs), 2000-2012
• Table 3.14: Worldwide Central Lab Glucose Testing (Hospitals and Reference Labs), 2000-2012
• Table 3.15: Worldwide Glucose Self-Testing Market Sales (Meters, Strips, Lancets), 2000-2012
• Table 3.16: Worldwide Glucose Market for Self-Testing Sales (Meters, Strips, Lancets), 2000-2012
• Table 3.17: Glucose Market for Self-Testing and POC Devices in the U.S., 2000-2012
• Table 3.18: U.S. Blood Glucose Reagent Strip Market, 2000-2012
• Table 3.19: OTC Glucose Meter U.S. Market Share for Blood Glucose Measurements
• Table 3.20: U.S. Diabetes Glucose Monitoring Market Repeat Retail Replacement Sales Percentages
• Table 3.21: Top Four Players in the U.S. Blood Glucose Strips Market (Ranked by % Sales), 2006
• Table 3.22: Leading Blood Glucose Meters and Strips Brands in the U.S. (% Breakdown by Dollar Sales), 2006
• Table 3.23: European Glucose Self-Testing Market (Meters, Strips, Lancets), 2000-2012
• Table 3.24: European Glucose Self-Testing Market by Country Market
• Table 3.25: Asian Glucose Self-Testing Market (Meters, Strips, Lancets), 2000-2012
• Table 3.26: Japanese Glucose Self-Testing Market (Meters, Strips, Lancets), 2000-2012
• Table 3.27: Chinese Glucose Self-Testing Market (Meters, Strips, Lancets), 2000-2012
• Table 3.28: China Blood Glucose Reagent Strip Market, 2000-2012
• Table 3.29: Indian IVD Market, 2006-2012
• Table 3.30: Number of Automated Clinical Labs in India, 2004-2012
• Table 3.31: Indian IVD Market, 2006
• Table 3.32: Indian Glucose Self-Testing Market (Meters, Strips, Lancets), 2000-2012
• Table 3.33: Indian Blood Glucose Reagent Strip Market, 2000-2012
• Table 3.34: ROW Glucose Self-Testing Market (Meters, Strips, Lancets), 2000-2012
• Table 3.35: Unit Sales of Homecare Lancets in the U.S., 2000-2012
• Table 3.36: Unit Sales of Lancets in the E.U., 2000-2012
• Table 3.37: Dollar Sales of Lancets in the U.S., 2000-2012
• Table 3.38: Dollar Sales of Lancets in the E.U., 2000-2012
• Table 3.39: Unit Sales of Homecare Glucose Self-testing Lancets in the U.S., 2000-2012
• Table 3.40: Unit Sales of Homecare Glucose Self-testing Lancets in the E.U., 2000-2012
• Table 3.41: Competition in the Lancet Market Segment
• Table 3.42: Technology of Glucose Testing Instruments
• Table 3.43: Key Features of Reagent Test Strips
• Table 3.44: Limitations of Urine Glucose Monitoring
• Table 3.45: Advantages of Urine Glucose Monitoring
• Table 3.46: Blood Ketone Reading Indications
• Table 3.47: Customer Priorities-Glucose Meter Self-Testing Market
• Table 3.48: Accu-Chek Blood Glucose Monitoring Systems
• Table 3.49: GlucoTrack Comparison and Results
• Table 3.50: Home Diagnostics' Current Product Portfolio
• Table 3.51: Relationship of A1c to Average Whole Blood and Plasma Glucose Levels
• Table 3.52: Distributors of Glucose Meters
• Table 3.53: Ultra-Large Clinical Chemistry Analyzers
• Table 3.54: JEOL Analyzer Comparison
• Table 3.55: Large Clinical Chemistry Analyzers
• Table 3.56: Mid-size Clinical Chemistry Analyzers
• Table 3.57: Small Clinical Chemistry Analyzers
• Table 4.1: U.S. Diabetes Glucose Monitoring Market Segments
• Table 4.2: Medicare Billing Guidelines for Multichannel Chemistry Tests
• Table 5.1: Customized Reports must Support CAP and JCAHO Requirements
• Table 5.2: RALS-Plus Point of Care Market Share
• Table 5.3: Applications of RALS Connectivity with POCT Devices
• Table 6.1: Comparisons of Blood Glucose Monitoring Systems
• Table 6.2: U.S. Diabetes Glucose Monitoring Market, 2006
• Table 6.3: Syringes for Administering Insulin
• Table 6.4: Insulin Pens
• Table 6.5: Injection Aids
• Table 6.6: Jet Injectors
• Table 6.7: External Insulin Pumps
• Table 6.8: Insulin Delivery Device Market, 2004-2014
• Table 7.1: Products Marketed by Abbott in the Diagnostic Market
• Table 7.2: Key Roche Diagnostic Products